Markets
MNK

Relypsa (RLYP) Worth Watching: Stock Gains 13.3% - Tale of the Tape

Relypsa, Inc. ( RLYP ) was a big mover last session with its shares rising over 13% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company as the stock is now trading above past one month's volatile price range of $22.61 to $24.98.

This pharmaceutical company has seen no estimate revision over the past 30 days. However, the Zacks Consensus Estimate has moved higher over the same period. This implies solid trading potential for the company. So make sure to keep an eye on this stock going forward to see if Friday's rally can turn into more strength down the road.

Relypsa currently has a Zacks Rank #3 (Hold) while its Earnings ESP is 0.00%.

Investors interested in the Medical Drug industry may consider better-ranked stocks like Akorn Inc. ( AKRX ), Mallinckrodt plc ( MNK ) and KaloBios Pharmaceuticals, Inc. ( KBIO ). While Akorn and Mallinckrodt sport a Zacks Rank #1 (Strong Buy), KaloBios bears a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days . Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

RELYPSA INC (RLYP): Free Stock Analysis Report

AKORN INC (AKRX): Free Stock Analysis Report

MALLINCKRODT PL (MNK): Free Stock Analysis Report

KALOBIOS PHARMA (KBIO): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

MNK

Other Topics

Investing Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More